ProTide technology is a powerful drug strategy that enables you to realize the benefits of nucleotide therapeutics. By masking polar phosphate functionality, ProTides aim to overcome the poor pharmacokinetics associated with nucleotides. Their clever mechanism of action relies on harnessing the intracellular metabolic machinery to release and activate the desired nucleotide once it has safely entered the recipient’s cell.
The constant improvement in ProTide chemical structures, and the understanding of their complex in-vivo behaviour, has led to several regulatory approvals to treat hepatitis B (HBV) and C (HCV) and, more recently, COVID-19 infections. However, numerous hurdles have yet to be overcome to fully realize the benefit of ProTides.
Join our panel of scientific experts as they review the challenges associated with the discovery of ProTides, their synthesis, and bioanalysis. They will also present cutting-edge strategies to help you successfully overcome the challenges.
- Graeme Clark – Vice-President of Bioanalysis and DMPK
- Thomas Pesnot – Head of Medicinal Chemistry
Who should attend?
- Any scientist with an interest in prodrug pharmaceutical research (industrial, biotech or pharma).